ArticleJAMA network open2024
Incidence and Survival Outcomes of Gastrointestinal Stromal Tumors.
Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Article
- A Tale of Two Pathways: Same-Surgeon Versus Different-Surgeon Resection After Second Surgical Opinion.Journal of surgical oncology · 2026Article
- Machine learning based on preoperative CT for noninvasive prediction of recurrence-free survival in gastrointestinal stromal tumors.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Optimizing Surgical Strategies and Prognostic Outcomes in Duodenal Gastrointestinal Stromal Tumors.Annals of surgical oncology · 2026Article
- Minimally invasive transgastric resection of gastric GIST is a feasbile alternative to wedge resection.Surgical endoscopy · 2026Article
- Neoadjuvant Imatinib Therapy in Rectal Gastrointestinal Stromal Tumors: A Comprehensive Narrative Review of Tumor Downsizing, Sphincter Preservation, Transanal Surgical Platforms, Functional Outcomes, and Survival.Journal of gastrointestinal cancer · 2026Review
- Jejunal Gastrointestinal Stromal Tumor Presenting as Life-Threatening Melena and Profound Anemia: A Case Report.Cureus · 2026Article
- Comparison of laparoscopic versus open approach surgery for gastric gastrointestinal stromal tumors in unfavorable surgical locations.BMC cancer · 2026Article
- Development and validation of CT-based nomograms for predicting recurrence and prognosis in gastrointestinal stromal tumor.Abdominal radiology (New York) · 2026Article
- Retrospective study on clinical outcomes and safety evaluation of da Vinci robot-assisted laparoscopy and endoscopic cooperative for small gastric stromal tumors resection: preliminary single-center experience.Journal of gastrointestinal oncology · 2026Article
- Imaging Strategies and Research Advances in Gastrointestinal Stromal Tumors.Current treatment options in oncology · 2026Review
- Endoscopic full-thickness resection of upper gastrointestinal stromal tumors: a retrospective study from a large tertiary hospital in China.Surgical endoscopy · 2026Article
- Rare co-occurrence of gastrointestinal stromal tumors and leiomyomas: A case report and review of the literature.Experimental and therapeutic medicine · 2026Article
- Article
- Research progress on the application of dual energy CT in gastric diseases.Frontiers in medicine · 2026Review
- Acute gastrointestinal hemorrhage as the sole initial manifestation of gastric leiomyosarcoma: a case report highlighting the discrepancy between preoperative assessment and final pathology.Frontiers in oncology · 2026Article
- Uncovering the associative mediation pathway from EUS features to malignancy through pathological mediators in gastrointestinal stromal tumor.Frontiers in medicine · 2026Article
- Case Report: a giant gastric stromal tumor spontaneously hemorrhaged after freeze-dried rabies vaccine (Vero-cells) injection for human use.Frontiers in oncology · 2026Article
- Comprehensive Molecular Screening by Next Generation Sequencing of Gastrointestinal Stromal Tumors (GISTs): In Silico Analysis and Classification of Rare KIT Exon 11 Mutations.Cancer medicine · 2025Article
- The feasibility and safety of laparoscopic limited resection for duodenal gastrointestinal stromal tumor: a propensity score-matched analysis.Surgical endoscopy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The incidence of gastrointestinal stromal tumors (GISTs) increased after the implementation of GIST-specific histology coding in 2001, but updated data on trends and survival are lacking. Objective: To examine the evolving epidemiology of GISTs in major organ sites. Design, Setting, and Participants: This descriptive, population-based cohort study used nationally representative data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, including the SEER-22 and SEER-17 registries. Data were from evaluated patients aged 20 years or older with GISTs diagnosed between January 1, 2000, and December 31, 2019. Analyses were last updated on October 29, 2023. Main Outcomes and Measures: Organ site-specific trends in age-standardized incidence rates and annual percent changes (APCs) in rates were estimated by race and ethnicity and, when possible, by sex, age, and primary indicator. Multivariable Cox proportional hazards regression models were used to examine racial and ethnic differences in overall and GIST-specific survival by site. Results: The SEER-22 and SEER-17 datasets contained 23 001 and 12 109 case patients with GISTs, respectively. Patients in the SEER-22 registry had a mean (SD) age of 64 (13) years and 51.3% were men. With regard to race and ethnicity, 9.7% of patients were Asian or Pacific Islander, 12.3% were Hispanic, 19.6% were non-Hispanic Black, and 57.7% were non-Hispanic White. Overall incidence rates of GISTs in the SEER-22 cohort increased substantially over time for all organ sites but the colon (APCs: esophagus, 7.3% [95% CI, 4.4% to 10.2%]; gastric, 5.1% [95% CI, 4.2% to 6.1%]; small intestine, 2.7% [95% CI, 1.8% to 3.7%]; colon, -0.2% [95% CI, -1.3% to 0.9%]; and rectum, 1.9% [95% CI, 0.1% to 3.8%]). There were similar increasing trends by age groups (<50 vs ≥50 years), sex, race and ethnicity, and primary indicator for gastric and small intestine GISTs. Increases were mainly restricted to localized stage disease. Patients in the SEER-17 cohort had a mean (SD) age of 64 (14) years and 51.9% were men. With regard to race and ethnicity, 13.3% of patients were Asian or Pacific Islander, 11.6% were Hispanic, 17.8% were non-Hispanic Black, and 56.6% were non-Hispanic White. Non-Hispanic Black individuals had higher overall mortality for esophageal (adjusted hazard ratio [HR], 6.4 [95% CI, 2.0 to 20.3]) and gastric (adjusted HR, 1.4 [95% CI, 1.2 to 1.5]) GISTs compared with non-Hispanic White individuals. Asian or Pacific Islander individuals also had higher overall mortality for esophageal GISTs (adjusted HR, 5.6 [95% CI, 1.5 to 20.2]). Results were similar for GIST-specific survival. Conclusions and Relevance: In this cohort study using SEER data, the incidence of GISTs in major organ sites increased in the last 2 decades among several population groups. These findings suggest that additional studies are warranted to identify risk factors, because histologic reclassification and higher availability of endoscopy and imaging do not fully explain these unfavorable incidence trends. Prevention efforts are needed to reduce the substantial survival disparities among racial and ethnic minoritized populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.